About Cadrenal Therapeutics
Cadrenal Therapeutics is a company based in Ponte Vedra Beach (United States) founded in 2022 by Quang Pham.. Cadrenal Therapeutics has raised $400 thousand across 3 funding rounds. The company has 4 employees as of December 31, 2024. Cadrenal Therapeutics offers products and services including Tecarfarin. Cadrenal Therapeutics operates in a competitive market with competitors including Moderna, Calliditas Therapeutics, Enyo Pharma, Unicycive and Akebia Therapeutics, among others.
- Headquarter Ponte Vedra Beach, United States
- Employees 4 as on 31 Dec, 2024
- Founders Quang Pham
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cadrenal Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-10.65 M-27.45as on Dec 31, 2024
-
EBITDA
$-10.96 M-43.61as on Dec 31, 2024
-
Total Equity Funding
$400 K (USD)
in 3 rounds
-
Latest Funding Round
-
Investors
-
Employee Count
4
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cadrenal Therapeutics
Cadrenal Therapeutics is a publicly listed company on the NASDAQ with ticker symbol CVKD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cadrenal Therapeutics
Cadrenal Therapeutics offers a comprehensive portfolio of products and services, including Tecarfarin. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A vitamin K antagonist offering stable anticoagulation for cardiac patients.
Unlock access to complete
Unlock access to complete
Funding Insights of Cadrenal Therapeutics
Cadrenal Therapeutics has successfully raised a total of $400K across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(25 Jul 2022)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2023 | Amount | Post-IPO - Cadrenal Therapeutics | Valuation |
investors |
|
| Dec, 2022 | Amount | Seed - Cadrenal Therapeutics | Valuation |
investors |
|
| Jul, 2022 | Amount | Seed - Cadrenal Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Cadrenal Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cadrenal Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cadrenal Therapeutics Comparisons
Competitors of Cadrenal Therapeutics
Cadrenal Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Calliditas Therapeutics, Enyo Pharma, Unicycive and Akebia Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Therapeutics are developed for diseases with impaired kidney function.
|
|
| domain | founded_year | HQ Location |
Small molecule therapies for kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for various kidney diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cadrenal Therapeutics
Frequently Asked Questions about Cadrenal Therapeutics
When was Cadrenal Therapeutics founded?
Cadrenal Therapeutics was founded in 2022.
Where is Cadrenal Therapeutics located?
Cadrenal Therapeutics is headquartered in Ponte Vedra Beach, United States. It is registered at Ponte Vedra Beach, Florida, United States.
Who is the current CEO of Cadrenal Therapeutics?
Quang Pham is the current CEO of Cadrenal Therapeutics. They have also founded this company.
Is Cadrenal Therapeutics a funded company?
Cadrenal Therapeutics is a funded company, having raised a total of $400K across 3 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Jul 25, 2022.
How many employees does Cadrenal Therapeutics have?
As of Dec 31, 2024, the latest employee count at Cadrenal Therapeutics is 4.
What does Cadrenal Therapeutics do?
Cadrenal Therapeutics was founded in 2022 and is based in Ponte Vedra Beach, United States. Focus is placed on the biotechnology sector, where therapeutics for renal disease and atrial fibrillation are developed. The lead candidate, Tecarfarin, is advanced as an anticoagulation drug to prevent systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. Operations center on drug development for these conditions.
Who are the top competitors of Cadrenal Therapeutics?
Cadrenal Therapeutics's top competitors include Moderna, Calliditas Therapeutics and Enyo Pharma.
What products or services does Cadrenal Therapeutics offer?
Cadrenal Therapeutics offers Tecarfarin.
Is Cadrenal Therapeutics publicly traded?
Yes, Cadrenal Therapeutics is publicly traded on NASDAQ under the ticker symbol CVKD.
What is Cadrenal Therapeutics's ticker symbol?
The ticker symbol of Cadrenal Therapeutics is CVKD on NASDAQ.